Refer to my posts with Draey and Earlsfield last week. Personally, from reading RNS with SAR and VAL with PYC concerning their Compound Modelling, I think PYC will receive a payment ( a small %) everytime SAR and VAL receive payment including licensing deals.
If I'm right, PYC should announce a RNS about this within the next 2 months.
Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce the attainment of a US$2.0 million success milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, Inc. (NASDAQ: SRRA), formerly, until today, ProNAi Therapeutics, Inc.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.